LY 3113593

Drug Profile

LY 3113593

Alternative Names: LY3113593

Latest Information Update: 09 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Class
  • Mechanism of Action Bone morphogenetic protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anaemia

Most Recent Events

  • 22 Jun 2016 Eli Lilly completes a phase I trial for Anaemia (In patients with chronic kidney disease) in USA (IV) (NCT02604160)
  • 25 Jan 2016 Phase-II clinical trials in Anaemia in USA (Parenteral) before January 2016
  • 01 Aug 2015 Eli Lilly completes a phase I trial in Anaemia in USA (NCT02144285)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top